The BrainChild studies are for children, teens and young adults with brain tumors (including DIPG, diffuse midline glioma, high grade glioma, medulloblastoma, ependymoma, ATRT, ETMR, pineoblastoma) who: Does CAR T-cell therapy work against CNS tumors?.What is the best dose of intra-CNS-delivered CAR T cells for children and young adults with CNS tumors?.Is CAR T-cell therapy safe to give to children and young adults with relapsed or refractory CNS tumors (tumors of the brain or spinal cord)?.Through the BrainChild studies, researchers are working to answer these questions:
CAR TCEL HOW TO
Phase 1 trials focus on finding out how much of a therapy to give, how to give it, how often to give it and when side effects occur. The BrainChild studies are phase 1 clinical trials. What is the goal of the BrainChild studies? Learn more about Seattle Children’s comprehensive Brain Tumor Program.
In this trial, a patient’s own T cells are reprogrammed to recognize and target four proteins at the same time. BrainChild-04 (targets B7-H3, EGFR, HER2, and IL13-Zetakine).Learn more about this and other clinical trials at Seattle Children's.įor more information, call 20 or send us an email.Read more about the BrainChild-03 protocol at.The study began in November 2019 and is currently recruiting patients.
CAR TCEL TRIAL
This is the first CAR T-cell trial at Seattle Children's and one of the first in the world for children with DIPG and is open to patients with DIPG any time after radiation. This study is open to patients with all types of CNS tumors that have recurred or progressed and for children with DIPG. Placement will depend on the location of the tumor. The reprogrammed cells (now CAR T cells) will be put back into a patient’s brain through a catheter, either into the place where the tumor has been removed or into the CNS ventricular system (intra-CNS). In this trial, a patient’s own T cells are reprogrammed to recognize and target the protein B7-H3, which is expressed on many pediatric CNS tumors but not healthy brain tissue.
0 kommentar(er)
